Danone confirmed on January 21, 2026 that it has blocked a specially manufactured batch of infant formula destined for Singapore at the explicit request of the Singapore Food Agency (SFA). The batch, comprising approximately 250,000 tins produced across its Wexford, Ireland, facility in early January, was held prior to export after routine quality‐control data flagged a minor deviation in nutrient analysis. While no safety concerns have been reported by end‐users, Danone said it suspended the shipment to comply fully with SFA protocols and is conducting additional assays on the batch. Singapore represents roughly 1.5% of Danone’s 2025 net sales—about €65 million—primarily in its early‐life nutrition segment. Management indicated that the blocked batch will be retested and, if cleared, released for sale by late February, with a minimal impact on first‐quarter revenues. Danone’s stock reacted modestly in early trading, reflecting investor confidence in the company’s adherence to stringent quality standards and transparent engagement with regulatory bodies.